Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ.
Adult
Aged
Aged, 80 and over
Animals
Biomarkers, Tumor
Breast Neoplasms
/ metabolism
Cancer-Associated Fibroblasts
/ metabolism
Carcinoma, Intraductal, Noninfiltrating
/ metabolism
Cell Communication
Cell Line, Tumor
Coculture Techniques
Computational Biology
/ methods
Disease Models, Animal
Epithelial Cells
/ metabolism
Female
Gene Expression Profiling
Humans
Immunohistochemistry
Mice
Middle Aged
Neoplasm Grading
Prognosis
Receptors, Platelet-Derived Growth Factor
/ genetics
Stromal Cells
/ metabolism
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 09 2019
01 09 2019
Historique:
received:
22
11
2017
revised:
13
11
2018
accepted:
21
12
2018
pubmed:
1
3
2019
medline:
17
6
2020
entrez:
1
3
2019
Statut:
ppublish
Résumé
A better definition of biomarkers and biological processes related to local recurrence and disease progression is highly warranted for ductal breast carcinoma in situ (DCIS). Stromal-epithelial interactions are likely of major importance for the biological, clinical, and pathological distinctions between high- and low-risk DCIS cases. Stromal platelet derived growth factor receptor (PDGFR) was immunohistochemically assessed in two DCIS patient cohorts (n = 458 and n = 80). Cox proportional hazards models were used to calculate the hazard ratios of recurrence. The molecular mechanisms regulating stromal PDGFR expression were investigated in experimental in vitro co-culture systems of DCIS cells and fibroblasts and analyzed using immunoblot and quantitative real-time PCR. Knock-out of JAG1 in DCIS cells and NOTCH2 in fibroblasts was obtained through CRISPR/Cas9. Experimental data were validated by mammary fat pad injection of DCIS and DCIS-JAG1 knock-out cells (10 mice per group). All statistical tests were two-sided. PDGFRα(low)/PDGFRβ(high) fibroblasts were associated with increased risk for recurrence in DCIS (univariate hazard ratio = 1.59, 95% confidence interval [CI] = 1.02 to 2.46; P = .04 Wald test; multivariable hazard ratio = 1.78, 95% CI = 1.07 to 2.97; P = .03). Tissue culture and mouse model studies indicated that this fibroblast phenotype is induced by DCIS cells in a cell contact-dependent manner. Epithelial Jagged1 and fibroblast Notch2 were identified through loss-of-function studies as key juxtacrine signaling components driving the formation of the poor prognosis-associated fibroblast phenotype. A PDGFRα(low)/PDGFRβ(high) fibroblast subset was identified as a marker for high-risk DCIS. The Jagged-1/Notch2/PDGFR stroma-epithelial pathway was described as a novel signaling mechanism regulating this poor prognosis-associated fibroblast subset. In general terms, the study highlights epithelial-stromal crosstalk in DCIS and contributes to ongoing efforts to define clinically relevant fibroblast subsets and their etiology.
Sections du résumé
BACKGROUND
A better definition of biomarkers and biological processes related to local recurrence and disease progression is highly warranted for ductal breast carcinoma in situ (DCIS). Stromal-epithelial interactions are likely of major importance for the biological, clinical, and pathological distinctions between high- and low-risk DCIS cases.
METHODS
Stromal platelet derived growth factor receptor (PDGFR) was immunohistochemically assessed in two DCIS patient cohorts (n = 458 and n = 80). Cox proportional hazards models were used to calculate the hazard ratios of recurrence. The molecular mechanisms regulating stromal PDGFR expression were investigated in experimental in vitro co-culture systems of DCIS cells and fibroblasts and analyzed using immunoblot and quantitative real-time PCR. Knock-out of JAG1 in DCIS cells and NOTCH2 in fibroblasts was obtained through CRISPR/Cas9. Experimental data were validated by mammary fat pad injection of DCIS and DCIS-JAG1 knock-out cells (10 mice per group). All statistical tests were two-sided.
RESULTS
PDGFRα(low)/PDGFRβ(high) fibroblasts were associated with increased risk for recurrence in DCIS (univariate hazard ratio = 1.59, 95% confidence interval [CI] = 1.02 to 2.46; P = .04 Wald test; multivariable hazard ratio = 1.78, 95% CI = 1.07 to 2.97; P = .03). Tissue culture and mouse model studies indicated that this fibroblast phenotype is induced by DCIS cells in a cell contact-dependent manner. Epithelial Jagged1 and fibroblast Notch2 were identified through loss-of-function studies as key juxtacrine signaling components driving the formation of the poor prognosis-associated fibroblast phenotype.
CONCLUSIONS
A PDGFRα(low)/PDGFRβ(high) fibroblast subset was identified as a marker for high-risk DCIS. The Jagged-1/Notch2/PDGFR stroma-epithelial pathway was described as a novel signaling mechanism regulating this poor prognosis-associated fibroblast subset. In general terms, the study highlights epithelial-stromal crosstalk in DCIS and contributes to ongoing efforts to define clinically relevant fibroblast subsets and their etiology.
Identifiants
pubmed: 30816935
pii: 5366926
doi: 10.1093/jnci/djy234
pmc: PMC6748730
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Platelet-Derived Growth Factor
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
983-995Informations de copyright
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Cancer Res. 2002 Oct 1;62(19):5476-84
pubmed: 12359756
Cancer Res. 2004 Apr 15;64(8):2725-33
pubmed: 15087386
Clin Cancer Res. 2008 Apr 1;14(7):1956-65
pubmed: 18381933
Cancer Cell. 2008 May;13(5):394-406
pubmed: 18455123
Circ Res. 2008 Jun 20;102(12):1483-91
pubmed: 18483410
Circ Res. 2009 Feb 27;104(4):466-75
pubmed: 19150886
Arthritis Rheum. 2009 Feb;60(2):428-39
pubmed: 19180482
Breast Cancer Res. 2009;11(1):R7
pubmed: 19187537
Curr Opin Genet Dev. 2009 Feb;19(1):67-73
pubmed: 19211240
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3372-7
pubmed: 19218449
BMC Bioinformatics. 2009 May 27;10:161
pubmed: 19473525
Am J Pathol. 2009 Jul;175(1):334-41
pubmed: 19498003
Cancer Biol Ther. 2009 Jun;8(11):1071-9
pubmed: 19502809
J Natl Cancer Inst. 2010 Feb 3;102(3):170-8
pubmed: 20071685
PLoS One. 2010 May 20;5(5):e10747
pubmed: 20505768
Blood. 2010 Sep 30;116(13):2385-94
pubmed: 20558614
Dev Cell. 2010 Jul 20;19(1):78-89
pubmed: 20643352
BMC Cancer. 2010 Nov 30;10:653
pubmed: 21118480
Dis Model Mech. 2011 Mar;4(2):165-78
pubmed: 21324931
Vasc Cell. 2011 Jan 18;3(1):2
pubmed: 21349159
Breast Cancer Res Treat. 2011 Oct;129(3):929-38
pubmed: 21537936
Breast Cancer Res Treat. 2012 Jun;133(3):889-98
pubmed: 22052326
Biochim Biophys Acta. 2013 Jul;1832(7):1070-8
pubmed: 23123598
Cancer Res. 2013 Feb 15;73(4):1287-97
pubmed: 23243022
Cancer Res. 2013 Apr 1;73(7):2139-49
pubmed: 23338608
Cancer Res. 2013 Mar 15;73(6):1721-32
pubmed: 23345161
Mol Oncol. 2013 Oct;7(5):859-69
pubmed: 23890733
Cell Cycle. 2013 Aug 15;12(16):2684-90
pubmed: 23907124
Eur J Cancer. 2014 Feb;50(3):517-24
pubmed: 24275214
Int J Breast Cancer. 2013;2013:582134
pubmed: 24490077
Nat Rev Drug Discov. 2014 May;13(5):357-78
pubmed: 24781550
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
Nat Cell Biol. 2014 Aug;16(8):717-27
pubmed: 25082194
Clin Cancer Res. 2015 Mar 1;21(5):955-61
pubmed: 25388163
Cell. 2014 Oct 23;159(3):499-513
pubmed: 25417103
Nat Cell Biol. 2015 Sep;17(9):1193-204
pubmed: 26302407
Hum Pathol. 2016 Mar;49:114-23
pubmed: 26826418
Oncotarget. 2016 Apr 5;7(14):18573-84
pubmed: 26918345
Stem Cell Reports. 2016 May 10;6(5):643-651
pubmed: 27066863
Acta Oncol. 2016 Nov;55(11):1338-1343
pubmed: 27548561
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
J Clin Pathol. 2017 Feb;70(2):102-108
pubmed: 27864452
J Pathol Clin Res. 2016 Sep 14;3(1):38-43
pubmed: 28138400
Int J Epidemiol. 2017 Dec 1;46(6):1740-1741g
pubmed: 28180256
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Sci Rep. 2017 Feb 24;7:43378
pubmed: 28233816
Cancer Discov. 2017 Oct;7(10):1098-1115
pubmed: 28652380
J Intern Med. 2018 Jan;283(1):16-44
pubmed: 28940884
Adv Drug Deliv Rev. 2017 Nov 1;121:117-123
pubmed: 28970051
Breast Cancer Res Treat. 2018 Jun;169(2):231-241
pubmed: 29380207
Nat Med. 2018 May;24(4):463-473
pubmed: 29529015
Arch Gynecol. 1982;231(3):209-18
pubmed: 6289760
Cancer Res. 1981 Dec;41(12 Pt 1):5076-81
pubmed: 7030483
Science. 1997 Jul 11;277(5323):225-8
pubmed: 9211848
Horm Res. 1998;50 Suppl 2:7-14
pubmed: 9721586